Table 1.
Methodological details of biomarker measurements
| Molecule | Manufacturer (Antibodies/Kit) | Serum | CSF | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Dilution factor | Lower detection limita | Intra‐assay variationb | Inter‐assay variationb | Dilution factor | Lower detection limita | Intra‐assay variationb | Inter‐assay variationb | ||
| IL‐12p40 | Meso Scale Diagnostics, Rockville, MD (K15050D) | n.a. | n.a. | n.a. | n.a. | 1 | 1.6 pg/mL | 7.6% | 8.8% |
| sCD21 | R&D Systems (MAB4909, BAF4909) | 200 | 688.7 pg/mL | 3.4% | 4.5% | 2 | 12.2 pg/mL | 2.6% | 4.1% |
| sCD27 | Sanquin, Amsterdam, the Netherlands (M1960) | n.a. | n.a. | n.a. | n.a. | 20 | 0.4 U/mL | 3.6% | 4.3% |
| CXCL13 | R&D Systems (MAB801, BAF801) | 10 | 254.2 pg/mL | 2.3% | 9.7% | 1 | 25.5 pg/mL | 4.8% | 8.1% |
| BAFF | R&D Systems (DY124) | 10 | 11.6 pg/mL | 4.9% | 7.2% | 3 | 2.1 pg/mL | 4.7% | 8.6% |
| Rituximab | AbD Serotec, Oxford, UK (HCA186, MCA2260) | 5 | 83.0 pg/mL | 9.5% | 7.5% | 2 | 37.5 pg/mL | 3.6% | 7.1% |
| NFL | UmanDiagnostics, Umea, Sweden (10‐7001) | n.a. | n.a. | n.a. | n.a. | 2 | 200 pg/mL | 2.9% | 6.0% |
IL‐12p40, interleukin (IL)‐12p40; sCD21, soluble CD21; CXCL13, C‐X‐C motif chemokine 13; BAFF, B‐cell activating factor; NFL, Neurofilament light protein; n.a., not applicable.
a
When diluted CSF was used, detection limit is recalculated to reflect the utilized concentration factor.
b
Median value of concentration CV.